全文获取类型
收费全文 | 1368453篇 |
免费 | 103356篇 |
国内免费 | 6611篇 |
专业分类
耳鼻咽喉 | 17072篇 |
儿科学 | 44067篇 |
妇产科学 | 36715篇 |
基础医学 | 201327篇 |
口腔科学 | 36587篇 |
临床医学 | 133940篇 |
内科学 | 262984篇 |
皮肤病学 | 26676篇 |
神经病学 | 113143篇 |
特种医学 | 49294篇 |
外国民族医学 | 381篇 |
外科学 | 187501篇 |
综合类 | 34746篇 |
现状与发展 | 8篇 |
一般理论 | 462篇 |
预防医学 | 116771篇 |
眼科学 | 29977篇 |
药学 | 102619篇 |
30篇 | |
中国医学 | 5252篇 |
肿瘤学 | 78868篇 |
出版年
2021年 | 12781篇 |
2019年 | 12782篇 |
2018年 | 17540篇 |
2017年 | 13471篇 |
2016年 | 14311篇 |
2015年 | 16838篇 |
2014年 | 22860篇 |
2013年 | 33949篇 |
2012年 | 46867篇 |
2011年 | 49682篇 |
2010年 | 29000篇 |
2009年 | 26474篇 |
2008年 | 44593篇 |
2007年 | 46794篇 |
2006年 | 46866篇 |
2005年 | 44949篇 |
2004年 | 42604篇 |
2003年 | 40395篇 |
2002年 | 39075篇 |
2001年 | 61453篇 |
2000年 | 63116篇 |
1999年 | 52856篇 |
1998年 | 14976篇 |
1997年 | 13661篇 |
1996年 | 13453篇 |
1995年 | 12785篇 |
1994年 | 11920篇 |
1993年 | 11089篇 |
1992年 | 41746篇 |
1991年 | 40905篇 |
1990年 | 39554篇 |
1989年 | 37434篇 |
1988年 | 34685篇 |
1987年 | 33786篇 |
1986年 | 32230篇 |
1985年 | 30693篇 |
1984年 | 23057篇 |
1983年 | 19606篇 |
1982年 | 11758篇 |
1979年 | 20813篇 |
1978年 | 14816篇 |
1977年 | 12064篇 |
1976年 | 11877篇 |
1975年 | 12111篇 |
1974年 | 14800篇 |
1973年 | 14472篇 |
1972年 | 13357篇 |
1971年 | 12418篇 |
1970年 | 11485篇 |
1969年 | 10410篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
13.
14.
T. Wu L. G. Trahair M. J. Bound C. F. Deacon M. Horowitz C. K. Rayner K. L. Jones 《Diabetic medicine》2015,32(5):595-600
15.
Feasibility and Diagnostic Potential of Pulmonary Transit Time Measurement by Contrast Echocardiography: A Pilot Study 下载免费PDF全文
16.
Eric S. Zhou Larissa Nekhlyudov Sharon L. Bober 《Translational andrology and urology》2015,4(2):218-231
There is a large and growing population of long-term cancer survivors. Primary care physicians (PCPs) are playing an increasingly greater role in the care of these patients across the continuum of cancer survivorship. In this role, PCPs are faced with the responsibility of managing a range of medical and psychosocial late effects of cancer treatment. In particular, the sexual side effects of treatment which are common and have significant impact on quality of life for the cancer survivor, often go unaddressed. This is an area of clinical care and research that has received increasing attention, highlighted by the presentation of this special issue on Cancer and Sexual Health. The aims of this review are 3-fold. First, we seek to overview common presentations of sexual dysfunction related to major cancer diagnoses in order to give the PCP a sense of the medical issues that the survivor may present with. Barriers to communication about sexual health issues between patient/PCPs in order are also described in order to emphasize the importance of PCPs initiating this important conversation. Next, we provide strategies and resources to help guide the PCP in the management of sexual dysfunction in cancer survivors. Finally, we discuss case examples of survivorship sexual health issues and highlight the role that a PCP can play in each of these case examples. 相似文献
17.
18.
19.
Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers 下载免费PDF全文
20.